As of March 31, 2026, Cellectis (CLLS) had $188 million in consolidated cash, cash equivalents, restricted cash and fixed-term deposits classified as current financial assets. The Company believes its cash, cash equivalents and fixed-term deposits will be sufficient to fund its operations into Q4 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLLS:
- Cellectis Files Q1 2026 Interim Financials with U.S. SEC
- Cellectis Q1 2026 Results Highlight CAR-T Pipeline Milestones, New Epigenetic Platform and Licensing Dispute
- CLLS Earnings this Week: How Will it Perform?
- Cellectis to Release First-Quarter 2026 Results on May 11
- Cellectis Showcases Safer Epigenetic Gene-Silencing Platform Ahead of ASGCT 2026